glp 1 drugs covered by insurance CMS Issues Coverage Guidance on GLP-1 Anti-Obesity How Employers Can Manage GLP-1
Description
doi: 10.1007/s00125-023-05962-z
4 Orforglipron continues to demonstrate notable glycemic and weight effects in phase II trials
Semaglutide (Ozempic, Wegovy) may worsen diabetic retinopathy in patients with pre-existing retinal disease who experience rapid blood sugar improvements, but it does not directly damage eye structures
ODT formulations have not undergone clinical trials and their effectiveness has not been established.
Essentially, they slow down the gastric emptying, increasing the feeling of fullness
